Elina Jerschow, MD in Rochester, MN - Medicare Allergy/immunology

Elina Jerschow, MD is a medicare enrolled "Allergy & Immunology" physician in Rochester, Minnesota. She graduated from medical school in 1996 and has 28 years of diverse experience with area of expertise as Allergy/immunology. She is a member of the group practice Mayo Clinic and her current practice location is 200 1st St Sw, Rochester, Minnesota. You can reach out to her office (for appointments etc.) via phone at (507) 284-2511.

Elina Jerschow is licensed to practice in Minnesota (license number 71101) and she also participates in the medicare program. She may accept medicare assignments (which means she may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance) and her NPI Number is 1922197235.

Contact Information

	Elina Jerschow, MD
	200 1st St Sw, Rochester, MN 55905-0001
	(507) 284-2511
	Not Available

Physician's Profile

Full Name	Elina Jerschow
Gender	Female
Speciality	Allergy/immunology
Experience	28 Years
Location	200 1st St Sw, Rochester, Minnesota
Accepts Medicare Assignments	May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance.

Medical Education and Training:

Elina Jerschow graduated from medical school in 1996

NPI Data:

NPI Number: 1922197235
Provider Enumeration Date: 10/12/2006
Last Update Date: 06/23/2022

Medicare PECOS Information:

PECOS PAC ID: 8426115700
Enrollment ID: I20220518001967

Medical Identifiers

Medical identifiers for Elina Jerschow such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1922197235	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207K00000X	Allergy & Immunology	71101 (Minnesota)	Primary
207R00000X	Internal Medicine	002315 (New York)	Secondary
207RA0201X	Internal Medicine - Allergy & Immunology	71101 (Minnesota)	Secondary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Mayo Clinic	6507778255	4232

News Archive

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

New initiative to reduce racial and ethnic disparities in infant mortality

HHS Secretary Tommy G. Thompson announced last night during a visit to Navajo Country $4.25 million to support a new initiative to reduce racial and ethnic disparities in infant mortality.

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Elina Jerschow allows following entities to bill medicare on her behalf.

Entity Name	Mayo Clinic
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285

News Archive

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

New initiative to reduce racial and ethnic disparities in infant mortality

HHS Secretary Tommy G. Thompson announced last night during a visit to Navajo Country $4.25 million to support a new initiative to reduce racial and ethnic disparities in infant mortality.

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Elina Jerschow is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Elina Jerschow, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511	Elina Jerschow, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511

News Archive

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

New initiative to reduce racial and ethnic disparities in infant mortality

HHS Secretary Tommy G. Thompson announced last night during a visit to Navajo Country $4.25 million to support a new initiative to reduce racial and ethnic disparities in infant mortality.

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Allergy & Immunology Doctors in Rochester, MN

Jenny Maribel Montejo, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511
Gerald W Volcheck, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511
Elizabeth C Ender, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511
Dr. Rohit Dilip Divekar, M.D, PH.D Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511
Dr. Ingrid V Neel, Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 210 9th St Se, Rochester, MN 55904 Phone: 507-288-3443
Thanai Pongdee, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511
Dr. Anupama Ravi, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511

Elina Jerschow, MD - Medicare Allergy/immunology in Rochester, MN

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

New initiative to reduce racial and ethnic disparities in infant mortality

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Medicare Reassignments

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

New initiative to reduce racial and ethnic disparities in infant mortality

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

New initiative to reduce racial and ethnic disparities in infant mortality

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Allergy & Immunology Doctors in Rochester, MN